February 14, 2024
Otsuka Pharmaceutical said on February 13 that its investigational agent AVP-786 failed to achieve the primary goal in a PIII clinical study targeting agitation associated with dementia due to Alzheimer’s disease. The drug could not yield a statistically significant difference...read more